Organ Protection With Sevoflurane Postconditioning After Cardiac Surgery With Cardiopulmonary Bypass

This study has been completed.
Information provided by (Responsible Party):
University of Zurich Identifier:
First received: June 17, 2009
Last updated: October 11, 2011
Last verified: October 2011

Organ protection, volatile anesthetics, postconditioning.

Sedation of patients on ICU after cardiac surgery with cardiopulmonary bypass with either propofol or sevoflurane. Evaluation of organ function and inflammatory mediators in the blood.

Condition Intervention
Cardiac On-pump Surgery
Drug: Sevoflurane
Drug: Propofol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Myocardial injury markers (myoglobin, creatine kinase, myocard specific creatine kinase, and troponin T) [ Time Frame: Start and end of ICU stay ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Oxygenation index, postoperative pulmonary complications, ICU stay (days), length of hospitalisation [ Time Frame: Start with surgery until end of hospitalisation ] [ Designated as safety issue: No ]

Enrollment: 120
Study Start Date: October 2007
Study Completion Date: December 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sevoflurane Drug: Sevoflurane
Sedation with sevoflurane
Drug: Propofol
Sedation on intensive care unit with propofol
Experimental: Propofol Drug: Sevoflurane
Sedation with sevoflurane
Drug: Propofol
Sedation on intensive care unit with propofol


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • CABG and/or heart valve surgery with CPB
  • Ejection fraction (EF) = 30%
  • Canadian Cardiovascular Society (CCS) classification = 3
  • Ages 18 to 90 years old

Exclusion criteria:

  • Pulmonary disease: forced expiratory volume in one second (FEV1) < 80%; FEV1/forced vital capacity (FVC) < 70%
  • Renal disease and/ or creatinine-clearance < 60 ml/min
  • Previous cardiac surgery
  • Emergency procedures
  • Postoperative intra aortic balloon pump (IABP) requirement
  • Myocardial infarction < 7d
  • Steroid treatment
  • Insulin-dependent diabetes
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00924222

Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Zurich Identifier: NCT00924222     History of Changes
Other Study ID Numbers: IFA-5-2007 
Study First Received: June 17, 2009
Last Updated: October 11, 2011
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Anesthetics, General
Anesthetics, Inhalation
Anesthetics, Intravenous
Central Nervous System Depressants
Hypnotics and Sedatives
Physiological Effects of Drugs
Platelet Aggregation Inhibitors processed this record on May 24, 2016